CORT logo

CORT Corcept Therapeutics Inc

$115.63
$0.47
(0.41%)
Today
Closed $115.63
$0.00
(0.00%)
After Hours
49

Neutral Sentiment

How do you feel about CORT?

Loading...
Corcept Announces Planned Leadership Transition
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of...
Business Wire
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Zacks
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European...
Business Wire
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years
Corcept Therapeutics (NASDAQ:CORT) has outperformed the market over the past 10 years by 20.4% on an annualized basis producing an average annual return of 33.86%. Currently, Corcept Therapeutics has a marketread more...
Benzinga
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Zacks
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months
Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.
Stocktwits